Preliminary Program
| DAY 1 – Friday, October 14, 2022 All timing in CEST |
|
| 10:00-10:10 | Welcome Address by Congress chairs |
| 10:10-11:10 | Session 1: Keynote Lectures Chairs: Judith Trotman, Australia & Stefano Luminari, Italy |
| 10:10-10:30 | What is the new classification bringing to the lymphoma landscape? Daphne de Jong, Netherlands |
| 10:30-10:50 | How COVID impacts on risk-based selection of lymphoma care Sean Lim, UK |
| 10:50-11:10 | Roundtable discussion All speakers and chairs |
| 11:10-12:10 | Session 2: Can we do better in risk stratification of lymphoma patients? Chairs: Judith Trotman, Australia & Stefano Luminari, Italy |
| 11:10-11:30 | Radiomics in lymphoma: TMTV, Dmax and beyond TBA |
| 11:30-11:50 | Liquid biopsy in lymphomas: From technical aspects to its clinical use Mark Roschewski, USA |
| 11:50-12:10 | Roundtable discussion All speakers and chairs |
| 12:10-13:10 | Industry symposium timeslot |
| 13:10-15:10 | Session 3: Hodgkin’s lymphoma Chairs: Mehdi Hamadani, USA & Anna Sureda, Spain |
| 13:10-13:40 | Debate: Should BV-AVD be the new standard of care for advanced stage cHL? |
| 13:10–13:25 | Yes: TBA |
| 13:25–13:40 | No: Paul Bröckelmann, Germany |
| 13:40-14:10 | Debate: Is radiotherapy still needed for early stage cHL? |
| 13:40-13:55 | Yes: Carmen Martinez, Spain |
| 13:55-14:10 | No: Wendy Osborne, UK |
| 14:10-14:40 | Debate: Triple refractory cHL (auto-HCT / BV / CPIs) are candidates for … |
| 14:10-14:25 | Allo-HCT: Carmello Carlo-Stella, Italy |
| 14:25-14:40 | CAR T cells: Sairah Ahmed, USA |
| 14:40-15:10 | Roundtable discussion All speakers and chairs |
| 15:10-17:10 | Session 4: Large B cell lymphomas: First-line therapy Chairs: Mehdi Hamadani, USA & Nilanjan Ghosh, USA |
| 15:10-15:40 | Debate: Is Pola-R-CHP the new standard of care for DLBCL? |
| 15:10–15:25 | Yes: Laurie Sehn, Canada |
| 15:25–15:40 | No: Nilanjan Ghosh, USA |
| 15:40-16:10 | Debate: Is R-DA-EPOCH the standard of care for double hit lymphomas? |
| 15:40-15:55 | Yes: Kieron Dunleavy, USA |
| 15:55-16:10 | No: Martina Pennisi, Italy |
| 16:10-16:40 | Debate: Should CNS prophylaxis be used in patients with high-risk aggressive B-cell lymphoma? |
| 16:10-16:25 | Yes: TBA |
| 16:25-16:40 | No: Matthew Wilson, UK |
| 16:40-17:10 | Roundtable discussion All speakers and chairs |
| 17:10-19:00 | Session 5: Large B cell lymphomas: The relapse setting Chairs: John Kuruvilla, Canada & Anna Sureda, Spain |
| 17:10-17:20 | Are improvements of salvage strategies in relapsed / refractory patients with DLBCL possible? Christopher Fox, UK |
| 17:20-17:50 | Debate: Is CART cell therapy one-size-fits-all for primary refractory and early relapse patents with DLBCL? |
| 17:20-17:35 | Yes: TBA |
| 17:35-17:50 | No: Alberto Mussetti, Spain |
| 17:50-18:20 | Debate: Curing relapses after CART cell therapy |
| 17:50-18:05 | With BiEsp: Michael Dickinson, Australia |
| 18:05-18:20 | With Allo-HCT: Mazyar Shadman, USA |
| 18:20-19:00 | Roundtable discussion All speakers and chairs |
| DAY 2 – Saturday, October 15, 2022 All timing in CEST |
|
| 10:00-11:30 | Session 6: Mantle cell lymphoma Chairs: Marek Trněný, Czech Republic & Eva Giné, Spain |
| 10:00-10:30 | Debate: How will BTK inhibitors reshape first line therapy? |
| 10:00-10:15 | Young patients: Eliza Hawkes, Australia |
| 10:15-10:30 | Elderly patients: Mats Jerkeman, Sweden |
| 10:30-11:00 | Debate: Conquering MCL in Second line |
| 10:30-10:45 | BTK inhibitors: TBA |
| 10:45-11:00 | CAR T cells : Marie José Kersten, Netherlands |
| 11:00-11:30 | Roundtable discussion All speakers and chairs |
| 11:30-13:00 | Session 7: CNS lymphomas Chairs: Andres Ferreri, Italy & Gerald Illerhaus, Germany |
| 11:30-12:00 | Debate: Best induction therapy must include thiotepa |
| 11:30-11:45 | Yes: Kate Cwynarski, UK |
| 11:45-12:00 | No: TBA |
| 12:00-12:30 | Debate: Consolidation strategies in 1st CR should consider … |
| 12:00-12:15 | Auto-HCT: TBA |
| 12:15-12:30 | Radiotherapy: TBA |
| 12:30-13:00 | Roundtable discussion All speakers and chairs |
| 13:00-14:00 | Industry symposium timeslot |
| 14:00-16:10 | Session 8: Follicular lymphoma Chairs: Judith Trotman, Australia & Stefano Luminari, Italy |
| 14:00-14:30 | Debate: Is W&W still an option for newly diagnosed follicular lymphoma? |
| 14:00-14:15 | Yes: Elizabeth Phillips, UK |
| 14:15-14:30 | No: TBA |
| 14:30-14:50 | Chemo-free strategies as first-line therapy Lia Palomba, USA |
| 14:50-15:10 | Towards a better identification of POD24 patients Carla Casulo, USA |
| 15:10-15:40 | Debate: Is there any role for HCT in relapsed/refractory FL in 2022? |
| 15:10-15:25 | Yes: Timothy Fenske, USA |
| 15:25-15:40 | No: Caron Jacobson, USA |
| 15:40-16:10 | Roundtable discussion All speakers and chairs |
| 16:10-18:00 | Session 9: Small lymphocytic lymphoma / Chronic lymphocytic leukemia Chair: Toby Eyre, UK |
| 16:10-16:40 | Debate: Best first-line treatment strategy |
| 16:10-16:20 | BTK inhibitors: Farrukh Awan, USA |
| 16:20-16:30 | BCL-2 inhibitors: Mary Ann Anderson, Australia |
| 16:30-16:40 | Chemoimmunotherapy: TBA |
| 16:40-17:00 | Are MRD directed therapies ready for prime time? Tanya Sidiqqi, USA |
| 17:00-17:30 | Debate: Best therapy for triple refractory SLL/CLL patients (BTKi, BCL-2, PI3Ki) |
| 17:00-17:15 | Allo-HCT: TBA |
| 17:15-17:30 | CAR T cells: TBA |
| 17:30-18:00 | Roundtable discussion All speakers and chairs |
| 18:00-18:15 | Closing remarks by Congress chairs |